Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 6/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19675358 | 0.91 | ROCK2 (0.44) | ROCK2PLA2G4A | |
| SCHEMBL20250795 | 0.82 | THRA (0.49) | — | |
| SCHEMBL15882328 | 0.82 | ROCK2 (0.47) | ROCK2 | |
| SCHEMBL15882285 | 0.80 | ROCK2 (0.46) | ROCK2 | |
| SCHEMBL20646745 | 0.76 | ROCK2 (0.40) | ROCK2 | |
| SCHEMBL21948600 | 0.75 | ROCK2 (0.49) | ROCK2 | |
| SCHEMBL23889045 | 0.71 | ROCK2 (0.42) | ROCK2 | |
| SCHEMBL17452792 | 0.71 | ROCK2 (0.38) | ROCK2 | |
| SCHEMBL23889140 | 0.71 | KMT2A (0.35) | ROCK2PLA2G4A | |
| SCHEMBL20646991 | 0.70 | ROCK2 (0.45) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385026-B2 | Phthalazinones and isoquinolinones as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180162823-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162823-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | ROCK2 5/4885PLA2G4A 1056/4885PTPN1 400/4885 |
| US-10385026-B2 | Phthalazinones and isoquinolinones as rock inhibitors | MYLK, MYLK2, ROCK1 | ROCK2 5/4885PLA2G4A 1056/4885PTPN1 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.